These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 8416737

  • 1. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
    Sandlund JT, Neckers LM, Schneller HE, Woodruff LS, Magrath IT.
    Cancer Res; 1993 Jan 01; 53(1):127-32. PubMed ID: 8416737
    [Abstract] [Full Text] [Related]

  • 2. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
    Arasi VE, Lieberman R, Sandlund J, Kiwanuka J, Novikovs L, Kirsch I, Hollis G, Magrath IT.
    Cancer Res; 1989 Jun 15; 49(12):3235-41. PubMed ID: 2497974
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
    Cutrona G, Carpaneto EM, Ponzanelli A, Ulivi M, Millo E, Scarfì S, Roncella S, Benatti U, Boffa LC, Ferrarini M.
    Cancer Res; 2003 Oct 01; 63(19):6144-8. PubMed ID: 14559793
    [Abstract] [Full Text] [Related]

  • 4. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
    Jochner N, Eick D, Zimber-Strobl U, Pawlita M, Bornkamm GW, Kempkes B.
    EMBO J; 1996 Jan 15; 15(2):375-82. PubMed ID: 8617212
    [Abstract] [Full Text] [Related]

  • 5. Topological organization of the MYC/IGK locus in Burkitt's lymphoma cells assessed by nuclear halo preparations.
    Rätsch A, Joos S, Kioschis P, Lichter P.
    Exp Cell Res; 2002 Feb 01; 273(1):12-20. PubMed ID: 11795942
    [Abstract] [Full Text] [Related]

  • 6. Epstein-Barr virus and Burkitt's lymphoma.
    Magrath I, Jain V, Bhatia K.
    Semin Cancer Biol; 1992 Oct 01; 3(5):285-95. PubMed ID: 1335792
    [Abstract] [Full Text] [Related]

  • 7. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
    Polack A, Strobl L, Feederle R, Schweizer M, Koch E, Eick D, Wiegand H, Bornkamm GW.
    Oncogene; 1991 Nov 01; 6(11):2033-40. PubMed ID: 1945409
    [Abstract] [Full Text] [Related]

  • 8. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
    Jain VK, Judde JG, Max EE, Magrath IT.
    J Immunol; 1993 Jun 15; 150(12):5418-28. PubMed ID: 8515068
    [Abstract] [Full Text] [Related]

  • 9. c-MYC impairs immunogenicity of human B cells.
    Schlee M, Schuhmacher M, Hölzel M, Laux G, Bornkamm GW.
    Adv Cancer Res; 2007 Jun 15; 97():167-88. PubMed ID: 17419945
    [Abstract] [Full Text] [Related]

  • 10. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation.
    Leucci E, Cocco M, Onnis A, De Falco G, van Cleef P, Bellan C, van Rijk A, Nyagol J, Byakika B, Lazzi S, Tosi P, van Krieken H, Leoncini L.
    J Pathol; 2008 Dec 15; 216(4):440-50. PubMed ID: 18802929
    [Abstract] [Full Text] [Related]

  • 11. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
    Gerbitz A, Mautner J, Geltinger C, Hörtnagel K, Christoph B, Asenbauer H, Klobeck G, Polack A, Bornkamm GW.
    Oncogene; 1999 Mar 04; 18(9):1745-53. PubMed ID: 10208435
    [Abstract] [Full Text] [Related]

  • 12. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
    Strobl LJ, Kohlhuber F, Mautner J, Polack A, Eick D.
    Oncogene; 1993 Jun 04; 8(6):1437-47. PubMed ID: 8502472
    [Abstract] [Full Text] [Related]

  • 13. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
    Roland J, Morello D.
    Cell Growth Differ; 1993 Nov 04; 4(11):891-900. PubMed ID: 8297795
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc.
    Boffa LC, Cutrona G, Cilli M, Matis S, Damonte G, Mariani MR, Millo E, Moroni M, Roncella S, Fedeli F, Ferrarini M.
    Cancer Gene Ther; 2007 Feb 04; 14(2):220-6. PubMed ID: 17053816
    [Abstract] [Full Text] [Related]

  • 15. Two antisense promoters in the immunoglobulin mu-switch region drive expression of c-myc in the Burkitt's lymphoma cell line BL67.
    Apel TW, Mautner J, Polack A, Bornkamm GW, Eick D.
    Oncogene; 1992 Jul 04; 7(7):1267-71. PubMed ID: 1620543
    [Abstract] [Full Text] [Related]

  • 16. The role of immunoglobulin kappa elements in c-myc activation.
    Hörtnagel K, Mautner J, Strobl LJ, Wolf DA, Christoph B, Geltinger C, Polack A.
    Oncogene; 1995 Apr 06; 10(7):1393-401. PubMed ID: 7731690
    [Abstract] [Full Text] [Related]

  • 17. Forward and reverse changes in Ig/myc translocation carrying tumors.
    Klein G.
    Princess Takamatsu Symp; 1989 Apr 06; 20():135-42. PubMed ID: 2562178
    [Abstract] [Full Text] [Related]

  • 18. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
    Habel ME, Lemieux R, Jung D.
    J Cell Physiol; 2005 Apr 06; 203(1):277-85. PubMed ID: 15468060
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Expression of P0- and P3-RNA from the normal and translocated c-myc allele in Burkitt's lymphoma cells.
    Eick D, Polack A, Kofler E, Lenoir GM, Rickinson AB, Bornkamm GW.
    Oncogene; 1990 Sep 06; 5(9):1397-402. PubMed ID: 2216463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.